<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355–2" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355–2/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355–2/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355_2"><akn:num>355–2</akn:num><akn:heading>Actions for delays of generic drugs and biosimilar biological products</akn:heading><akn:content><akn:p>§ 355–2. Actions for delays of generic drugs and biosimilar biological products(a) DefinitionsIn this section—(1) the term “commercially reasonable, market-based terms” means—(A) a nondiscriminatory price for the sale of the covered product at or below, but not greater than, the most recent wholesale acquisition cost for the drug, as defined in section 1395w–3a(c)(6)(B) of title 42;

(B) a schedule for delivery that results in the transfer of the covered product to the eligible product developer consistent with the timing under subsection (b)(2)(A)(iv); and

(C) no additional conditions are imposed on the sale of the covered product;


(2) the term “covered product”—(A) means—(i) any drug approved under subsection (c) or (j) of section 355 of this title or biological product licensed under subsection (a) or (k) of section 262 of title 42;

(ii) any combination of a drug or biological product described in clause (i); or

(iii) when reasonably necessary to support approval of an application under section 355 of this title, or section 262 of title 42, as applicable, or otherwise meet the requirements for approval under either such section, any product, including any device, that is marketed or intended for use with such a drug or biological product; and


(B) does not include any drug or biological product that appears on the drug shortage list in effect under section 356e of this title, unless—(i) the drug or biological product has been on the drug shortage list in effect under such section 356e of this title continuously for more than 6 months; or

(ii) the Secretary determines that inclusion of the drug or biological product as a covered product is likely to contribute to alleviating or preventing a shortage.



(3) the term “device” has the meaning given the term in section 321 of this title;

(4) the term “eligible product developer” means a person that seeks to develop a product for approval pursuant to an application for approval under subsection (b)(2) or (j) o</akn:p></akn:content><akn:subsection eId="subsec_355_2_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions In this section—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_2_b"><akn:num>(b)</akn:num><akn:heading>Civil action for failure to provide sufficient quantities of a covered product</akn:heading><akn:content><akn:p>(b) Civil action for failure to provide sufficient quantities of a covered product</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_2_c"><akn:num>(c)</akn:num><akn:heading>Limitation of liability</akn:heading><akn:content><akn:p>(c) Limitation of liability A license holder for a covered product shall not be liable for any claim under Federal, State, or local law arising out of the failure of an eligible product developer to follow adequate safeguards to assure safe use of the covered product during development or testing activities described in this section, including transportation, handling, use, or disposal of the covered product by the eligible product developer.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_2_d"><akn:num>(d)</akn:num><akn:heading>Omitted</akn:heading><akn:content><akn:p>(d) Omitted</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_2_e"><akn:num>(e)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(e) Rule of construction</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_2_f"><akn:num>(f)</akn:num><akn:heading>Omitted</akn:heading><akn:content><akn:p>(f) Omitted</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355_2_g"><akn:num>(g)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(g) Rule of construction Nothing in this section, the amendments made by this section, or in section 355–1 of this title, shall be construed as—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>